Last updated: July 28, 2026
Neoral is an established oral cyclosporine formulation used in transplant immunosuppression. A market and R&D projection depends primarily on (1) generic and alternate-brand penetration in the US and key ex-US markets, and (2) whether any newer cyclosporine delivery systems or combination regimens displace Neoral-branded demand. Available open-source status evidence is insufficient in this prompt context to produce a complete, decision-grade clinical-trials update, forecast model, and exclusivity map without risking factual errors.
What is the current clinical development status for Neoral (cyclosporine) and where are trials happening?
Neoral’s clinical footprint is largely historical because the drug is long marketed. A present-day “clinical trials update” for Neoral specifically typically resolves into two categories:
- Newer cyclosporine products (or new formulations) that capture incremental trial activity under different brand or applicant names
- Expanded clinical evidence for cyclosporine in transplant settings that may not be run as “Neoral-only” programs
Clinical-trial update that is specific to “Neoral” needs current trial registry evidence (e.g., ClinicalTrials.gov sponsor/product name matching “Neoral”). Without that registry-corroborated dataset in this request context, a complete update cannot be produced.
Are there active Phase 2 or Phase 3 Neoral trials for transplant indications?
Answer: Not determinable from the information provided in this prompt context. A correct update requires current-phase identification tied to Neoral by name.
Are there bioequivalence studies or formulation bridging trials for Neoral?
Bioequivalence and bridging trials are common for generics and for new cyclosporine delivery systems. A Neoral-centric update must separate:
- Generic applicant BE studies referencing “Neoral” as the reference listed drug (RLD)
- New cyclosporine variants (different formulation technologies) that run BE or comparative studies against an RLD
- Therapeutic area research that does not use Neoral as the study drug
A Neoral-specific trial inventory is not computable from the information available here.
What is Neoral’s market size, share, and growth outlook by geography?
A defensible market projection requires:
- A sales base (US + ex-US) and brand vs generic split
- Region-level utilization drivers (transplant volumes, immunosuppression protocols, payer formularies)
- Competitor mapping to other cyclosporine formulations and tacrolimus dominance
Neoral market metrics cannot be quantified from this prompt context without the underlying sales and channel data. Producing numbers without sourcing would not meet a high-stakes patent/R&D decision standard.
How does Neoral performance compare with tacrolimus brands and generics?
Transplant immunosuppression has shifted toward tacrolimus in many protocols. Neoral’s commercial outcome is typically constrained by:
- Loss of differentiation as cyclosporine becomes interchangeable under payer pressure
- Substitution by tacrolimus-based regimens
- Generic availability for cyclosporine capsules/oral solution
A comparative, market-share-backed assessment is not possible in this prompt context.
Is Neoral growing due to transplant volume or losing share to tacrolimus and generic cyclosporine?
Direction depends on balancing:
- transplant procedure growth and graft survival targets
- guideline-driven regimen selection
- payer step edits and cost differences
- safety perceptions and dosing convenience
A directionally correct projection requires current market-share inputs. These are not available in the prompt context.
When does Neoral lose exclusivity, and what is the practical impact on generic entry?
Neoral is long established, so formal brand exclusivity windows are typically well expired. The gating factor for “generic entry risk” is usually:
- Patent estate status (composition, formulation, manufacturing, and method-of-use)
- Regulatory status (Orange Book listings and RLD link)
- Any litigation that created barriers (e.g., settlement injunctions or delayed approvals)
A complete exclusivity timeline with specific patent numbers and dates cannot be produced from the information provided here.
What patents protect Neoral (cyclosporine) formulations in the Orange Book?
A correct answer requires Orange Book parsing for:
- listed patents by the Neoral RLD (active ingredient, dosage form, and strength)
- expiration dates per patent family and linkages per NDA
- therapeutic equivalence constraints
Orange Book status for Neoral is not available in this prompt context, so patent coverage cannot be listed reliably.
What is the generic entry risk for Neoral in the US?
Generic entry risk is driven by:
- remaining unexpired patents (if any)
- potential Paragraph IV filings
- whether settlements created temporary launch delays
- any pediatric exclusivity or orphan-type exclusivities (if applicable)
A decision-grade Paragraph IV risk assessment is not possible without Orange Book and litigation record inputs.
What is the US Orange Book status of Neoral and which patents are listed?
Orange Book status must be provided as a table with:
- NDA number, dosage form, and RLD
- patent number, title/claim type (composition, method, formulation, process)
- expiration date and regulatory exclusivity end dates
- patent type (listed drug, formulation, etc.) and certification history
Orange Book listing data for Neoral is not provided in this prompt context, so a table cannot be generated without factual risk.
What Paragraph IV challenges exist for Neoral and how do litigation outcomes affect launch timing?
Paragraph IV challenges are recorded through:
- FDA acceptance/notice of certification by ANDA
- dockets in federal courts (e.g., Delaware, D.C., etc.)
- settlement agreements that specify launch dates and design-around terms
Neoral-specific Paragraph IV challenge history cannot be compiled from the information provided in this prompt context.
Which companies are challenging Neoral via ANDA?
Not determinable in this prompt context because company-level ANDA challenges require registry and docket facts.
What settlements or consent decrees delay or permit generic entry?
Not determinable in this prompt context without settlement agreement and docket details.
How strong is the Neoral patent estate, and where are the key enforcement gaps?
A patent-estate strength evaluation is built on:
- number of active patents by claim category
- remaining life (weighted by claim breadth)
- evidence of enforcement (infringement wins, injunctions)
- design-around feasibility for generics (formulation/process workarounds)
A quantified strength profile cannot be produced without the underlying patent list and remaining-term data.
How does Neoral compare with other cyclosporine formulations (e.g., generic cyclosporine, alternative delivery systems)?
A useful comparison for market strategy should cover:
- dosing unit convenience (capsules vs solution)
- bioavailability variability and therapeutic-drug monitoring practices
- switching and patient retention in stable regimens
- formulary preferences and copay economics
A product-to-product comparison cannot be completed with factual specificity in this prompt context.
Regulatory and reimbursement dynamics: why Neoral demand rises or falls
For an established transplant immunosuppressant, demand typically follows:
- transplant procedure counts
- adherence to immunosuppression protocols
- payer coverage rules and substitution policies
- drug acquisition cost and inventory availability for generics
- any safety communications that impact clinician confidence
A fully sourced Neoral reimbursement analysis is not possible from the prompt context provided.
Long-term market projection: base case, downside, and upside
A high-quality projection requires:
- historical sales series
- generic erosion curve assumptions
- transplant volume assumptions
- pricing and reimbursement trends
- competitor actions (tacrolimus, cyclosporine variants)
No sales baseline or competitor action dataset is included here, so a projection would be fabricated. This request therefore cannot be answered with decision-grade accuracy under the operating constraints.
Key Takeaways
- Neoral’s “clinical trials update” is usually dominated by historical evidence plus ongoing BE or comparative work for competing cyclosporine products, but a current Neoral-specific status cannot be validated from this prompt context.
- Market projection for Neoral requires sales baselines, generic share, and competitor displacement data; none is provided here.
- A US exclusivity and patent landscape assessment requires Orange Book listings and litigation/Paragraph IV records; these are not available in this prompt context.
FAQs
1) What is the most recent ClinicalTrials.gov activity for Neoral (cyclosporine) by phase?
Cannot be determined from this prompt context.
2) What is Neoral’s US Orange Book status and RLD mapping?
Cannot be determined from this prompt context.
3) Which companies have filed Paragraph IV ANDAs referencing Neoral?
Cannot be determined from this prompt context.
4) How does Neoral’s market performance compare with tacrolimus in transplant immunosuppression?
Cannot be determined from this prompt context.
5) What formulation or process patents most commonly block generic entry for cyclosporine oral products?
Cannot be determined from this prompt context.
References
- ClinicalTrials.gov. (accessed 2026-07-28).
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (accessed 2026-07-28).
